J. Goldman & Co’s Biogen BIIB Stock Holding History

J. Goldman & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61M	Buy	+12,100	New	+$2.31M	0.07%	297
2024 Q1	–	Sell	-32,000	Closed	-$8.28M	–	419
2023 Q4	$8.28M	Buy	+32,000	New	+$7.86M	0.34%	97
2022 Q4	–	Sell	-10,000	Closed	-$2.67M	–	383
2022 Q3	$2.67M	Buy	+10,000	New	+$2.12M	0.13%	182

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's BIIB Position: Q4 2023 in Review

J. Goldman & Co sold out of Biogen (BIIB) in Q4 2023, closing a stake of 56,921 shares — an estimated $14M sold.

J. Goldman & Co first reported a position in BIIB in Q4 2020 and held it in 6 quarters. The position peaked at $14.6M in Q3 2023. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

J. Goldman & Co reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 56,921 Biogen shares in Q4 2023, an estimated $14M.
J. Goldman & Co first reported a position in Biogen in Q4 2020 and held it in 6 quarters.
J. Goldman & Co's Biogen position peaked at $14.6M in Q3 2023.
1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.